Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mircera vs Darbepoetin Alfa for Anemia in Renal Transplant Recipients
NCT00605345Phase 3
Key facts
- Status
- Completed
- Start
- Dec 2007
- Primary completion
- Jul 2009
- Countries
- 1
- Sponsor
- Roche
- Modality
- rProtein (Recombinant Protein), Biologic
- Conditions
- anemia of chronic kidney disease
01
Overview
Phase 3, randomised, open-label trial of methoxy polyethylene glycol-epoetin beta in anemia of chronic kidney disease, sponsored by Roche. Primary endpoint: Percentage of Participants Maintaining Average Haemoglobin Concentration Within Target Range at 28 weeks. Started Dec 2007; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Adult kidney transplant recipients with stage 3 or 4 chronic kidney disease and a functioning graft (6 months to 10 years post-transplant) who are on stable maintenance subcutaneous darbepoetin alfa therapy.
04
Endpoints
Primary
Percentage of Participants Maintaining Average Haemoglobin Concentration Within Target Range
Beyond the preview
Go deeper on NCT00605345.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00605345.